Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis

PloS One
Nora SemrenSilke Meiners

Abstract

Proteasome inhibition has been shown to prevent development of fibrosis in several organs including the lung. However, effects of proteasome inhibitors on lung fibrosis are controversial and cytotoxic side effects of the overall inhibition of proteasomal protein degradation cannot be excluded. Therefore, we hypothesized that local lung-specific application of a novel, selective proteasome inhibitor, oprozomib (OZ), provides antifibrotic effects without systemic toxicity in a mouse model of lung fibrosis. Oprozomib was first tested on the human alveolar epithelial cancer cell line A549 and in primary mouse alveolar epithelial type II cells regarding its cytotoxic effects on alveolar epithelial cells and compared to the FDA approved proteasome inhibitor bortezomib (BZ). OZ was less toxic than BZ and provided high selectivity for the chymotrypsin-like active site of the proteasome. In primary mouse lung fibroblasts, OZ showed significant anti-fibrotic effects, i.e. reduction of collagen I and α smooth muscle actin expression, in the absence of cytotoxicity. When applied locally into the lungs of healthy mice via instillation, OZ was well tolerated and effectively reduced proteasome activity in the lungs. In bleomycin challenged mi...Continue Reading

References

Mar 20, 2004·Experimental & Molecular Medicine·Ji-Won LeeKyu-Won Kim
Dec 24, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michal SafranWilliam G Kaelin
Jan 18, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Serena FineschiCarlo Chizzolini
Jun 21, 2006·Free Radical Biology & Medicine·Silke MeinersKarl Stangl
Feb 24, 2007·Chemical Reviews·Ljudmila Borissenko, Michael Groll
Sep 21, 2007·Medicinal Research Reviews·Silke MeinersKarl Stangl
Oct 16, 2007·The International Journal of Biochemistry & Cell Biology·Antje MoellerMartin Kolb
May 7, 2008·American Journal of Respiratory Cell and Molecular Biology·Serena FineschiCarlo Chizzolini
Jun 6, 2009·Annual Review of Biochemistry·Daniel Finley
Feb 2, 2010·Drug Discovery Today·Lawrence R Dick, Paul E Fleming
Feb 18, 2010·Proceedings of the American Thoracic Society·Curtis H WeissManu Jain
Dec 24, 2010·Nephrology·Toru SakairiYoshihisa Nojima
Feb 24, 2011·The Journal of Biological Chemistry·Tsui-Fen Chou, Raymond J Deshaies
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
Jul 2, 2011·Lancet·Talmadge E KingMoisés Selman
Jul 6, 2011·The Journal of Experimental Medicine·Thomas A Wynn
Aug 13, 2011·Current Opinion in Pulmonary Medicine·Marios A Mouratis, Vassilis Aidinis
Aug 13, 2011·Nature Reviews. Drug Discovery·Luca RicheldiPeter Kirkpatrick
Sep 2, 2011·Inflammation·Suleyman Serdar KocaAhmet Isik
Sep 10, 2011·Drugs·Natalie J Carter
Sep 21, 2011·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Surinder M Soond, Andrew Chantry
Jul 18, 2012·Proceedings of the American Thoracic Society·Isis E Fernandez, Oliver Eickelberg
Aug 30, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yan ZangDaniel E Johnson
Oct 24, 2012·Biological Chemistry·Philipp BeckMichael Groll
Jan 25, 2013·Toxicology Mechanisms and Methods·Masanori HorieKatsuhide Fujita
Mar 19, 2013·Annual Review of Biochemistry·Robert J Tomko, Mark Hochstrasser
Mar 26, 2013·American Journal of Respiratory Cell and Molecular Biology·Verena AumillerMelanie Königshoff
Mar 26, 2013·American Journal of Respiratory Cell and Molecular Biology·Bethany B MooreCory M Hogaboam
Jun 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas M HerndonRichard Pazdur
Jan 21, 2014·Antioxidants & Redox Signaling·Silke MeinersAnne Caniard
May 20, 2014·The New England Journal of Medicine·Talmadge E KingUNKNOWN ASCEND Study Group
Aug 5, 2014·American Journal of Respiratory and Critical Care Medicine·Neil AhluwaliaAndrew M Tager

❮ Previous
Next ❯

Citations

Apr 26, 2019·Cardiovascular Research·Tanja HeitmeierDjuro Kosanovic

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
electrophoresis
PCR
bronchoalveolar
transfection

Software Mentioned

3DHISTECH
Panoramic Viewer

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

American Journal of Respiratory Cell and Molecular Biology
Daniel KassSteven Greenberg
American Journal of Physiology. Lung Cellular and Molecular Physiology
Ichiro InoshimaNobuyuki Hara
American Journal of Respiratory Cell and Molecular Biology
Serena FineschiCarlo Chizzolini
Proceedings of the National Academy of Sciences of the United States of America
William E LawsonTimothy S Blackwell
© 2021 Meta ULC. All rights reserved